News Pfizer suffers another hit to its GBT sickle cell portfolio Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal.
News FDA clears Precigen's rare tumour immunotherapy Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory papillomatosis, Papzimeos, its first product.
News NHS cleared to use AZ's Fasenra for rare autoimmune disease NICE backs NHS use of an AstraZeneca drug for one rare disease, but says it can't recommend a BioMarin therapy for another.
News FDA restricts use of bluebird's Skysona gene therapy The FDA has added a warning label to bluebird bio's Skysona, after launching a probe into cases of blood cancer linked to the gene therapy.
News Jazz gets FDA okay for Chimerix brain cancer drug Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations.
News Rumour mill says Novartis may want to buy Avidity Novartis has made an offer to acquire RNA therapeutic specialist Avidity Biosciences, according to an unconfirmed report.
News DNA testing can help right racial imbalance in breast cancer Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and black women.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
